Why the study?
Current heart failure therapies aim to prevent deleterious remodeling after myocardial infarction, but no therapies are available to replace lost cardiomyocytes.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Metabolic modulation of cardiomyocyte proliferation warrants no clinical adoption yet; leaves open hypothesis-generating strategies for cardiac regeneration.
Current therapies for heart failure aim to prevent the deleterious remodeling that occurs after MI injury, but currently no therapies are available to replace lost cardiomyocytes. Several organisms now being studied are capable of regenerating their myocardium by the proliferation of existing cardiomyocytes. In this review, we summarize the main metabolic pathways of the mammalian heart and how modulation of these metabolic pathways through genetic and pharmacological approaches influences cardiomyocyte proliferation and heart regeneration.
No takes yet. Share an insight, caveat, or question.
Menendez-Montes et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: